From the ‡Department of Surgery, Helsinki University Central Hospital, Helsinki, Finland; §Research Programs Unit, Translational Cancer Biology, University of Helsinki, Helsinki, Finland;
¶Glykos Finland Ltd., Helsinki, Finland;
Mol Cell Proteomics. 2015 Feb;14(2):277-88. doi: 10.1074/mcp.M114.041632. Epub 2014 Dec 1.
All human cells are covered by glycans, the carbohydrate units of glycoproteins, glycolipids, and proteoglycans. Most glycans are localized to cell surfaces and participate in events essential for cell viability and function. Glycosylation evolves during carcinogenesis, and therefore carcinoma-related glycan structures are potential cancer biomarkers. Colorectal cancer is one of the world's three most common cancers, and its incidence is rising. Novel biomarkers are essential to identify patients for targeted and individualized therapy. We compared the N-glycan profiles of five rectal adenomas and 18 rectal carcinomas of different stages by matrix-assisted laser desorption-ionization time-of-flight mass spectrometry. Paraffin-embedded tumor samples were deparaffinized, and glycans were enzymatically released and purified. We found differences in glycosylation between adenomas and carcinomas: monoantennary, sialylated, pauci-mannose, and small high-mannose N-glycan structures were more common in carcinomas than in adenomas. We also found differences between stage I-II and stage III carcinomas. Based on these findings, we selected two glycan structures: pauci-mannose and sialyl Lewis a, for immunohistochemical analysis of their tissue expression in 220 colorectal cancer patients. In colorectal cancer, poor prognosis correlated with elevated expression of sialyl Lewis a, and in advanced colorectal cancer, poor prognosis correlated with elevated expression of pauci-mannose. In conclusion, by mass spectrometry we found several carcinoma related glycans, and we demonstrate a method of transforming these results into immunohistochemistry, a readily applicable method to study biomarker expression in patient samples.
所有人类细胞都被聚糖覆盖,糖蛋白、糖脂和糖蛋白聚糖的碳水化合物单位。大多数聚糖定位于细胞表面,参与对细胞存活和功能至关重要的事件。糖基化在癌变过程中进化,因此癌相关糖结构是潜在的癌症生物标志物。结直肠癌是世界上三种最常见的癌症之一,其发病率正在上升。新型生物标志物对于确定需要靶向和个体化治疗的患者至关重要。我们通过基质辅助激光解吸电离飞行时间质谱法比较了 5 个直肠腺瘤和 18 个不同阶段的直肠癌的 N-糖谱。将石蜡包埋的肿瘤样本脱蜡,并通过酶促释放和纯化聚糖。我们发现腺瘤和癌之间的糖基化存在差异:单触角、唾液酸化、少甘露糖和小高甘露糖 N-聚糖结构在癌中比在腺瘤中更常见。我们还发现了 I-II 期和 III 期癌之间的差异。基于这些发现,我们选择了两种糖结构:少甘露糖和唾液酸化 Lewis a,用于对 220 名结直肠癌患者的组织表达进行免疫组织化学分析。在结直肠癌中,高表达唾液酸化 Lewis a 与预后不良相关,而在晚期结直肠癌中,高表达少甘露糖与预后不良相关。总之,通过质谱法,我们发现了几种癌相关聚糖,并证明了将这些结果转化为免疫组织化学的方法,这是一种可用于研究患者样本中生物标志物表达的易于应用的方法。